Evidence map›Paper›PMID 32444457›Full record

Trial reportDiabetes care2020

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.

Vlado Perkovic, Robert Toto, Mark E Cooper, Johannes F E Mann, Julio Rosenstock, Darren K McGuire, Steven E Kahn, Nikolaus Marx, John H Alexander, Bernard Zinman and 8 more

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Treatment adherence and the contemporary approach to treating type 2 diabetes mellitus.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2024
    Review
  12. Article
  13. Review
  14. [Linagliptin improves diabetic kidney disease in rats by promoting mitochondrial biogenesis through the AMPK/PGC-1Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023
    Article
  15. Comparative Efficacy of Novel Antidiabetic Drugs on Albuminuria Outcomes in Type 2 Diabetes: A Systematic Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 12 institutions in 5 countries.

Vlado PerkovicFaculty of Medicine, The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia vlado.perkovic@unsw.edu.au.ORCID 0000-0002-4257-7620
Robert TotoUniversity of Texas Southwestern Medical Center, Dallas, TX.
Mark E CooperDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Johannes F E MannKuratorium für Dialyse Kidney Centre, Munich, Germany.
Julio RosenstockDallas Diabetes Research Center, Dallas, TX.ORCID 0000-0001-8324-3275
Darren K McGuireUniversity of Texas Southwestern Medical Center, Dallas, TX.ORCID 0000-0002-6412-7989
Steven E KahnDivision of Metabolism, Endocrinology and Nutrition, Department of Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, WA.
Nikolaus MarxDepartment of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.ORCID 0000-0001-6141-634X
John H AlexanderDuke Clinical Research Institute, Duke Health, Durham, NC.
Bernard ZinmanLunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.ORCID 0000-0002-0041-1876
Egon PfarrBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Sven SchnaidtBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Thomas MeinickeBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Maximillian von EynattenBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Jyothis T GeorgeBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Odd Erik JohansenBoehringer Ingelheim Norway KS, Asker, Norway.ORCID 0000-0003-2470-0530
Christoph WannerORCID 0000-0001-9507-5301
CARMELINA investigators
Boehringer Ingelheim (Germany) · DEThe University of Texas Southwestern Medical Center · USBoehringer Ingelheim (Norway) · NOClinical Research Institute · USDallas Diabetes Research Center · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEMonash University · AUMount Sinai Hospital · CAUniversitätsklinikum Aachen · DEUniversity of Washington · USUniversity of Würzburg · DEUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveType 2 diabetes is a leading cause of kidney failure, but few outcome trials proactively enrolled individuals with chronic kidney disease (CKD). We performed secondary analyses of cardiovascular (CV) and kidney outcomes across baseline estimated glomerular filtration rate (eGFR) categories (≥60, 45 to <60, 30 to <45, and <30 mL/min/1.73 m RESEARCH DESIGN AND

methodsParticipants with CV disease and/or CKD were included. The primary outcome was time to first occurrence of CV death, nonfatal myocardial infarction, or nonfatal stroke (three-point major adverse CV event [3P-MACE]), with a secondary outcome of renal death, end-stage kidney disease, or sustained ≥40% decrease in eGFR from baseline. Other end points included progression of albuminuria, change in HbA

resultsA total of 6,979 subjects (mean age 65.9 years; eGFR 54.6 mL/min/1.73 m

conclusionsAcross all GFR categories, in participants with type 2 diabetes and CKD and/or CV disease, there was no difference in risk for linagliptin versus placebo on CV and kidney events. Significant reductions in risk for albuminuria progression and HbA

Indexed as

AgedCardiovascular DiseasesCardiovascular SystemDiabetes Mellitus, Type 2Diabetic NephropathiesDipeptidyl-Peptidase IV InhibitorsFemaleGlomerular Filtration RateHumansHypoglycemic AgentsIncidenceKidneyKidney Failure, ChronicLinagliptinMaleMiddle AgedDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsLinagliptin

Identifiers

PMID32444457
PMCPMC7372065
OpenAlexW3028183585

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.